Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | UCHL3 | P15374 | 2/20 | 0.38 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205913 | 0.94 | TYR (0.44) | TYRRAB9ANPC1SMN1; SMN2IDO1 | |
| SCHEMBL933030 | 0.88 | TYR (0.48) | TYRRAB9ANPC1SMN1; SMN2IDO1 | |
| SCHEMBL869709 | 0.88 | TYR (0.48) | TYRRAB9ANPC1SMN1; SMN2IDO1 | |
| SCHEMBL19043222 | 0.85 | LMNA (0.37) | RAB9ANPC1SMN1; SMN2LMNAPKM | |
| Propionaldehyde SCHEMBL4619414 | 0.83 | TYR (0.44) | TYRRAB9ANPC1SMN1; SMN2IDO1 | |
| SCHEMBL19043130 | 0.82 | FFAR1 (0.34) | SMN1; SMN2HTTL3MBTL1ALDH1A1S1PR1 | |
| SCHEMBL3243515 | 0.81 | ALDH1A1 (0.35) | LMNAALDH1A1S1PR1S1PR3KDM4E | |
| SCHEMBL1611924 | 0.81 | IDO1 (0.41) | TYRRAB9ANPC1SMN1; SMN2IDO1 | |
| SCHEMBL9674964 | 0.81 | GPR84 (0.43) | LMNAALDH1A1EPHX1 | |
| SCHEMBL6572567 | 0.79 | HDAC4 (0.39) | TYRRAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074712-B | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-20180282662-A1 | Process | GIVAUDAN S.A. (CH) | 2018-10-04 | — | — | US | claimed |
| EP-3218459-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2017-09-20 | — | — | EP | claimed |
| CN-107074712-A | In organic compound or associated improvement | 奇华顿股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| WO-2016074697-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-05-19 | — | — | WO | claimed |
| EP-3218459-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-09-03 | — | — | EP | disclosed |
| CN-107074712-B | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3218459-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2017-09-20 | — | — | EP | disclosed |
| CN-107074712-A | In organic compound or associated improvement | 奇华顿股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2016074697-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016074697-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-05-19 | — | — | WO | disclosed |
| WO-2013170072-A2 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NEUROP, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013170072-A2 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NEUROP, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | TYR 380/4885RAB9A 1488/4885NPC1 359/4885 |
| US-20180282662-A1 | Process | CUL4B, RNF10, BICRA | TYR 54/4885RAB9A 1254/4885NPC1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.